Risk factor
Strong trading liquidity
Profitability factor
Very favourable analyst view
About
Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical enterprise primarily focused on the research, development, production, and global commercialization of vaccines designed for human use. Its extensive product portfolio features key immunizations such as attenuated (live) herpes zoster and varicella vaccines, alongside a live, nasal, and freeze-dried influenza vaccine, and a rabies vaccine utilizing vero cell technology. This company was established in 2004 and is headquartered in Changchun, China.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of 688276.SS is 32.0 and suggests 79.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to